Literature DB >> 35382387

Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: A potential role of M2 polarization.

Hidekata Yasuoka1, Yuen Yu Angela Tam1, Yuka Okazaki1,2, Yuichi Tamura3, Koichi Matsuo4, Carol Feghali-Bostwick5, Tsutomu Takeuchi1, Masataka Kuwana1,2.   

Abstract

Objectives: To investigate the systemic sclerosis-related phenotype in fos-related antigen-1 transgenic mice and its underlying mechanisms.
Methods: Lung and skin sections of constitutive fos-related antigen-1 transgenic mice and wild-type mice were examined by tissue staining and immunohistochemistry. The tricuspid regurgitation pressure gradient was measured by transthoracic echocardiography with a Doppler technique. To assess the impact of fos-related antigen-1 expression on macrophage function, bone marrow-derived mononuclear cells were derived from mice that expressed fos-related antigen-1 under the control of doxycycline and wild-type littermates. These bone marrow-derived mononuclear cells were induced to differentiate into macrophages with or without doxycycline, and analyzed for gene and protein expression. Finally, lung explants obtained from systemic sclerosis patients and control donors were subjected to immunohistochemistry.
Results: The lungs of fos-related antigen-1 transgenic mice showed excessive fibrosis of the interstitium and thickening of vessel walls, with narrowing lumen, in an age-dependent manner. The tricuspid regurgitation pressure gradient was significantly elevated in fos-related antigen-1 transgenic versus control mice. Increased dermal thickness and the loss of subdermal adipose tissue were also observed in the fos-related antigen-1 transgenic mice. These changes were preceded by a perivascular infiltration of mononuclear cells, predominantly consisting of alternatively activated or M2 macrophages. Overexpressing fos-related antigen-1 in bone marrow-derived mononuclear cell cultures increased the expression of M2-related genes, such as Il10, Alox15, and Arg1. Finally, fos-related antigen-1-expressing M2 macrophages were increased in the lung tissues of systemic sclerosis patients. Conclusions: The fos-related antigen-1 transgenic mouse serves as a genetic model of systemic sclerosis that recapitulates the major vascular and fibrotic manifestations of the lungs and skin in systemic sclerosis patients. M2 polarization mediated by the up-regulation of fos-related antigen-1 may play a critical role in the development of systemic sclerosis.
© The Author(s) 2019.

Entities:  

Keywords:  Interstitial lung disease; macrophages; mouse model; pulmonary arterial hypertension; systemic sclerosis

Year:  2019        PMID: 35382387      PMCID: PMC8922645          DOI: 10.1177/2397198319838140

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  50 in total

1.  Peripheral blood fibrocytes: differentiation pathway and migration to wound sites.

Authors:  R Abe; S C Donnelly; T Peng; R Bucala; C N Metz
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

2.  Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses.

Authors:  Yao-Chun Wang; Fei He; Fan Feng; Xiao-Wei Liu; Guang-Ying Dong; Hong-Yan Qin; Xing-Bin Hu; Min-Hua Zheng; Liang Liang; Lei Feng; Ying-Min Liang; Hua Han
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 3.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

4.  Cardiomyopathy in murine models of systemic sclerosis.

Authors:  Paulius Venalis; Gábor Kumánovics; Hendrik Schulze-Koops; Alfiya Distler; Clara Dees; Pawel Zerr; Katrin Palumbo-Zerr; László Czirják; Zygmunt Mackevic; Ingrid E Lundberg; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

5.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

6.  Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis.

Authors:  Britta Maurer; Nicole Busch; Astrid Jüngel; Margarita Pileckyte; Renate E Gay; Beat A Michel; Georg Schett; Steffen Gay; Jörg Distler; Oliver Distler
Journal:  Circulation       Date:  2009-11-23       Impact factor: 29.690

7.  Fra-1/AP-1 impairs inflammatory responses and chondrogenesis in fracture healing.

Authors:  Toru Yamaguchi; Yasunari Takada; Kenta Maruyama; Kouji Shimoda; Yoshinori Arai; Nobuhito Nango; Naoto Kosaki; Hironari Takaishi; Yoshiaki Toyama; Koichi Matsuo
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

8.  Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production.

Authors:  Aline Bozec; Latifa Bakiri; Maria Jimenez; Thorsten Schinke; Michael Amling; Erwin F Wagner
Journal:  J Cell Biol       Date:  2010-09-13       Impact factor: 10.539

9.  Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide.

Authors:  Elena Tourkina; Michael Bonner; James Oates; Ann Hofbauer; Mathieu Richard; Sergei Znoyko; Richard P Visconti; Jing Zhang; Corey M Hatfield; Richard M Silver; Stanley Hoffman
Journal:  Fibrogenesis Tissue Repair       Date:  2011-07-01

10.  Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop.

Authors:  Ayako Masuda; Hidekata Yasuoka; Takashi Satoh; Yuka Okazaki; Yukie Yamaguchi; Masataka Kuwana
Journal:  Arthritis Res Ther       Date:  2013-07-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.